FRM
LRMR icon

Fox Run Management’s Larimar Therapeutics LRMR Stock Holding History

Fox Run Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,119
Closed -$47.9K – 1143
2026
Q1 		$47.9K Buy
+11,119
New +$44.4K 0.01% 856
2025
Q1 		– Sell
-23,770
Closed -$92K – 1085
2024
Q4 		$92K Buy
23,770
+68
+0.3% +$449 0.02% 813
2024
Q3 		$155K Buy
+23,702
New +$190K 0.03% 699

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Fox Run Management's LRMR Position: Q2 2026 in Review

Fox Run Management sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 11,119 shares — an estimated $47.9K sold.

Fox Run Management first reported a position in LRMR in Q3 2024 and held it in 3 quarters. The position peaked at $155K in Q3 2024. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Fox Run Management reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 11,119 Larimar Therapeutics shares in Q2 2026, an estimated $47.9K.
  • Fox Run Management first reported a position in Larimar Therapeutics in Q3 2024 and held it in 3 quarters.
  • Fox Run Management's Larimar Therapeutics position peaked at $155K in Q3 2024.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.